Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Express News | Cytek Biosciences Inc - to Not Replace COO Position, Opting to Restructure Organization
Cytek Biosciences: Williams to Accept CEO Position at Another Company >CTKB
Press Release: Cytek Announces Resignation of Chief Operating Officer Chris Williams
Cytek Biosciences Shares Are Trading Lower After COO Paul Christopher Williams Submitted His Resignation, Effective Sept. 27.
Cytek Biosciences COO Resigns, Signaling Leadership Changes
Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Maintains Target Price $8
Piper Sandler analyst David Westenberg maintains $Cytek Biosciences(CTKB.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 48.9
Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)
Express News | Cytek® Biosciences Achieves Iso 13485 Certification at San Diego Reagent Manufacturing Facility
Express News | Cytek Biosciences Inc : Stephens Cuts Target Price to $7.5 From $10
Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Cuts Target Price to $8
Piper Sandler analyst David Westenberg maintains $Cytek Biosciences(CTKB.US)$ with a buy rating, and adjusts the target price from $8.5 to $8.According to TipRanks data, the analyst has a success
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8
Cytek Biosciences Analyst Ratings
Express News | Cytek Biosciences Inc : Piper Sandler Cuts Target Price to $8 From $8.5
Cytek Biosciences: Hold Rating Amidst Mixed Performance and Cautious U.S. Market Outlook
Earnings Call Summary | Cytek Biosciences(CTKB.US) Q2 2024 Earnings Conference
Institutional Owners May Take Dramatic Actions as Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Recent 15% Drop Adds to One-year Losses
Cytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 Financial Results.
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Maintains Target Price $12
TD Cowen analyst Steven Mah maintains $Cytek Biosciences(CTKB.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 27.4% and a